Biovance 3L Ocular effective in patients with chronic ocular surface disease

Chima H, et al. Pilot evaluation of Biovance 3-layer amniotic membrane graft for ocular surface disease. Presented at: Optometry’s Meeting; June 21-24, 2023; Washington.

Chima H, et al. Pilot evaluation of Biovance 3-layer amniotic membrane graft for ocular surface disease. Presented at: Optometry’s Meeting; June 21-24, 2023; Washington.

WASHINGTON — Biovance 3L Ocular human amniotic membrane allograft improved best corrected visual acuity and symptoms of eye dryness in a small cohort of patients, according to a poster presentation at Optometry’s Meeting.

“Biovance 3L Ocular is a decellularized, dehydrated, ringless three-layer human amniotic allograft regulated by the FDA as a human tissue-based product under Section 361 of the Public Health Service Act,” study author Harmin J. Chima, OD, told Healio, explaining that the product is “intended for use as a biological membrane covering that provides the extracellular matrix and can be applied in a variety of ocular surface conditions.”

Chima and Michele Cianciolo, OD, both of West Point Optical Group in Cleveland, examined 18 eyes with a history of ocular surface disease, including dry eye disease with persistent epithelial defects or superficial punctate keratitis (n = 7), anterior basement membrane disease with recurrent corneal erosion (n = 5) or band keratopathy (n = 6).

At baseline, they administered the Standard Patients Evaluation of Eye Dryness (SPEED) questionnaire and determined participants’ BCVA.

Researchers placed Biovance 3L Ocular (Verséa Ophthalmics) on patients’ corneas and treated them with topical antibiotics and steroid therapy for the first 5 to 7 days. Participants were reevaluated at day 5, which included repeating the SPEED questionnaire and BCVA assessment.

According to results, the average SPEED score after graft placement was 3.6 compared with 9.9 at baseline, signifying improvement in symptoms and signs of eye dryness. Similarly, BCVA also improved after the procedure.

“The results of this study show how effective Biovance 3L Ocular, and potentially other decellularized membranes, can be in the treatment of ocular surface disease that does not respond to traditional therapies,” Chima said.